Literature DB >> 22720228

Annexin A2 is a new antigenic target for pancreatic cancer immunotherapy.

Lei Zheng1, Elizabeth M Jaffee.   

Abstract

In our recent publication (Zheng et al., PLoS ONE) we described the identification of annexin A2 as a new pancreatic cancer associated tumor antigen. Its involvement in pancreatic cancer progression and metastases supports its role as an antigenic target for the development of both therapeutic antibody and T cell immunotherapy.

Entities:  

Year:  2012        PMID： 22720228      PMCID： PMC3376961          DOI： 10.4161/onci.1.1.18017

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  9 in total

1.  Isolation of novel HLA-DR restricted potential tumor-associated antigens from the melanoma cell line FM3.

Authors:  T Halder; G Pawelec; A F Kirkin; J Zeuthen; H E Meyer; L Kun; H Kalbacher
Journal:  Cancer Res       Date:  1997-08-01       Impact factor: 12.701

2.  An immune response manifested by the common occurrence of annexins I and II autoantibodies and high circulating levels of IL-6 in lung cancer.

Authors:  F M Brichory; D E Misek; A M Yim; M C Krause; T J Giordano; D G Beer; S M Hanash
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-14       Impact factor: 11.205

3.  A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A Phase II trial of safety, efficacy, and immune activation.

Authors:  Eric Lutz; Charles J Yeo; Keith D Lillemoe; Barbara Biedrzycki; Barry Kobrin; Joseph Herman; Elizabeth Sugar; Steven Piantadosi; John L Cameron; Sara Solt; Beth Onners; Irena Tartakovsky; Miri Choi; Rajni Sharma; Peter B Illei; Ralph H Hruban; Ross A Abrams; Dung Le; Elizabeth Jaffee; Dan Laheru
Journal:  Ann Surg       Date:  2011-02       Impact factor: 12.969

Review 4.  Potential targets for pancreatic cancer immunotherapeutics.

Authors:  Lindzy F Dodson; William G Hawkins; Peter Goedegebuure
Journal:  Immunotherapy       Date:  2011-04       Impact factor: 4.196

5.  Autoantibodies against the fibrinolytic receptor, annexin 2, in antiphospholipid syndrome.

Authors:  Gabriela Cesarman-Maus; Nina P Ríos-Luna; Arunkumar B Deora; Bihui Huang; Rosario Villa; Maria del Carmen Cravioto; Donato Alarcón-Segovia; Jorge Sánchez-Guerrero; Katherine A Hajjar
Journal:  Blood       Date:  2006-02-21       Impact factor: 22.113

Review 6.  The role of annexin II in angiogenesis and tumor progression: a potential therapeutic target.

Authors:  Mahesh C Sharma; Meena Sharma
Journal:  Curr Pharm Des       Date:  2007       Impact factor: 3.116

7.  Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation.

Authors:  Dan Laheru; Eric Lutz; James Burke; Barbara Biedrzycki; Sara Solt; Beth Onners; Irena Tartakovsky; John Nemunaitis; Dung Le; Elizabeth Sugar; Kristen Hege; Elizabeth Jaffee
Journal:  Clin Cancer Res       Date:  2008-03-01       Impact factor: 12.531

8.  Tyrosine 23 phosphorylation-dependent cell-surface localization of annexin A2 is required for invasion and metastases of pancreatic cancer.

Authors:  Lei Zheng; Kelly Foley; Lanqing Huang; Ashley Leubner; Guanglan Mo; Kelly Olino; Barish H Edil; Masamichi Mizuma; Rajni Sharma; Dung T Le; Robert A Anders; Peter B Illei; Jennifer E Van Eyk; Anirban Maitra; Daniel Laheru; Elizabeth M Jaffee
Journal:  PLoS One       Date:  2011-04-29       Impact factor: 3.240

9.  Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients.

Authors:  Amy Morck Thomas; Lynn M Santarsiero; Eric R Lutz; Todd D Armstrong; Yi-Cheng Chen; Lan-Qing Huang; Daniel A Laheru; Michael Goggins; Ralph H Hruban; Elizabeth M Jaffee
Journal:  J Exp Med       Date:  2004-08-02       Impact factor: 14.307
  9 in total
  16 in total

Review 1.  Current progress in immunotherapy for pancreatic cancer.

Authors:  Kelly Foley; Victoria Kim; Elizabeth Jaffee; Lei Zheng
Journal:  Cancer Lett       Date:  2015-12-23       Impact factor: 8.679

2.  Plasminogen-stimulated airway smooth muscle cell proliferation is mediated by urokinase and annexin A2, involving plasmin-activated cell signalling.

Authors:  A G Stewart; Y C Xia; T Harris; S Royce; J A Hamilton; M Schuliga
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

3.  Heterogeneous Stromal Signaling within the Tumor Microenvironment Controls the Metastasis of Pancreatic Cancer.

Authors:  Agnieszka A Rucki; Kelly Foley; Pingbo Zhang; Qian Xiao; Jennifer Kleponis; Annie A Wu; Rajni Sharma; Guanglan Mo; Angen Liu; Jennifer Van Eyk; Elizabeth M Jaffee; Lei Zheng
Journal:  Cancer Res       Date:  2016-11-07       Impact factor: 12.701

Review 4.  Specificity delivers: therapeutic role of tumor antigen-specific antibodies in pancreatic cancer.

Authors:  Darshil T Jhaveri; Lei Zheng; Elizabeth M Jaffee
Journal:  Semin Oncol       Date:  2014-07-22       Impact factor: 4.929

5.  PD-1/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumors.

Authors:  Kevin C Soares; Agnieszka A Rucki; Annie A Wu; Kelly Olino; Qian Xiao; Yi Chai; Anthony Wamwea; Elaine Bigelow; Eric Lutz; Linda Liu; Sheng Yao; Robert A Anders; Daniel Laheru; Christopher L Wolfgang; Barish H Edil; Richard D Schulick; Elizabeth M Jaffee; Lei Zheng
Journal:  J Immunother       Date:  2015-01       Impact factor: 4.456

6.  T Cells Engineered against a Native Antigen Can Surmount Immunologic and Physical Barriers to Treat Pancreatic Ductal Adenocarcinoma.

Authors:  Philip D Greenberg; Sunil R Hingorani; Ingunn M Stromnes; Thomas M Schmitt; Ayaka Hulbert; J Scott Brockenbrough; Hieu Nguyen; Carlos Cuevas; Ashley M Dotson; Xiaoxia Tan; Jennifer L Hotes
Journal:  Cancer Cell       Date:  2015-10-29       Impact factor: 31.743

7.  Annexin A2 silencing inhibits invasion, migration, and tumorigenic potential of hepatoma cells.

Authors:  Hai-Jian Zhang; Deng-Fu Yao; Min Yao; Hua Huang; Li Wang; Mei-Juan Yan; Xiao-Di Yan; Xing Gu; Wei Wu; Shao-Lin Lu
Journal:  World J Gastroenterol       Date:  2013-06-28       Impact factor: 5.742

8.  Using Quantitative Seroproteomics to Identify Antibody Biomarkers in Pancreatic Cancer.

Authors:  Darshil T Jhaveri; Min-Sik Kim; Elizabeth D Thompson; Lanqing Huang; Rajni Sharma; Alison P Klein; Lei Zheng; Dung T Le; Daniel A Laheru; Akhilesh Pandey; Elizabeth M Jaffee; Robert A Anders
Journal:  Cancer Immunol Res       Date:  2016-02-03       Impact factor: 11.151

Review 9.  Vaccines for pancreatic cancer.

Authors:  Kevin C Soares; Lei Zheng; Barish Edil; Elizabeth M Jaffee
Journal:  Cancer J       Date:  2012 Nov-Dec       Impact factor: 3.360

10.  Tumour antigen expression in hepatocellular carcinoma in a low-endemic western area.

Authors:  K Sideras; S J Bots; K Biermann; D Sprengers; W G Polak; J N M IJzermans; R A de Man; Q Pan; S Sleijfer; M J Bruno; J Kwekkeboom
Journal:  Br J Cancer       Date:  2015-06-09       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.